{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:49:12Z","timestamp":1791607752753,"version":"4.3.4"},"reference-count":28,"publisher":"Japanese Society of Internal Medicine","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026]]},"DOI":"10.2169\/internalmedicine.8093-26","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:11:53Z","timestamp":1790633513000},"source":"Crossref","is-referenced-by-count":0,"title":["Endoscopic and Symptomatic Outcomes of Vonoprazan for Erosive Esophagitis Following Laparoscopic Sleeve Gastrectomy: An Exploratory Prospective Study"],"prefix":"10.2169","author":[{"given":"Hideharu","family":"Okanobu","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Boda","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Sakai","sequence":"additional","affiliation":[{"name":"Department of Surgery, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshitsune","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Yuge","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nami","family":"Mori","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Kobayakawa","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takenori","family":"Okada","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nozomu","family":"Kamei","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenkichi","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Surgery, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Wilson R, Aminian A, Tahrani AA. Metabolic surgery: a clinical update. Diabetes Obes Metab 23 (Suppl 1): 63-83, 2021.","DOI":"10.1111\/dom.14235"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Welbourn R, Hollyman M, Kinsman R, et al. Bariatric surgery worldwide: baseline demographic description and one-year outcomes from the Fourth IFSO Global Registry Report 2018. Obes Surg 29: 782-795, 2019.","DOI":"10.1007\/s11695-018-3593-1"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. DuPree CE, Blair K, Steele SR, et al. Laparoscopic sleeve gastrectomy in patients with preexisting gastroesophageal reflux disease: a national analysis. JAMA Surg 149: 328-334, 2014.","DOI":"10.1001\/jamasurg.2013.4323"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Gu L, Chen B, Du N, et al. Relationship between bariatric surgery and gastroesophageal reflux disease: a systematic review and meta-analysis. Obes Surg 29: 4105-4113, 2019.","DOI":"10.1007\/s11695-019-04218-3"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Matar R, Monzer N, Jaruvongvanich V, et al. Indications and outcomes of conversion of sleeve gastrectomy to Roux-en-Y gastric bypass: a systematic review and a meta-analysis. Obes Surg 31: 3936-3946, 2021.","DOI":"10.1007\/s11695-021-05463-1"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Oor JE, Roks DJ, \u00dcnl\u00fc \u00c7, et al. Laparoscopic sleeve gastrectomy and gastroesophageal reflux disease: a systematic review and metaanalysis. Am J Surg 211: 250-267, 2016.","DOI":"10.1016\/j.amjsurg.2015.05.031"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Tai CM, Huang CK, Lee YC, et al. Increase in gastroesophageal reflux disease symptoms and erosive esophagitis 1 year after laparoscopic sleeve gastrectomy among obese adults. Surg Endosc 27: 1260-1266, 2013.","DOI":"10.1007\/s00464-012-2593-9"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Ehlers AP, Thumma JR, Finks JF, et al. Evaluation of patient reported gastroesophageal reflux severity at baseline and at 1-year after bariatric surgery. Ann Surg 275: 1143-1148, 2022.","DOI":"10.1097\/SLA.0000000000004533"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Tsai YN, Tai CM, Tu HP, et al. Factors associated with increased severity of erosive esophagitis 1 year after laparoscopic sleeve gastrectomy. Obes Surg 32: 3891-3899, 2022.","DOI":"10.1007\/s11695-022-06268-6"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Hori Y, Matsukawa J, Takeuchi T, et al. A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals. J Pharmacol Exp Ther 337: 797-804, 2011.","DOI":"10.1124\/jpet.111.179556"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Ashida K, Sakurai Y, Hori T, et al. Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther 43: 240-251, 2016.","DOI":"10.1111\/apt.13461"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Hoshino S, Kawami N, Takenouchi N, et al. Efficacy of vonoprazan for proton pump inhibitor-resistant reflux esophagitis. Digestion 95: 156-161, 2017.","DOI":"10.1159\/000456072"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Miyazaki H, Igarashi A, Takeuchi T, et al. Vonoprazan versus proton-pump inhibitors for healing gastroesophageal reflux disease: a systematic review. J Gastroenterol Hepatol 34: 1316-1328, 2019.","DOI":"10.1111\/jgh.14664"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Xiao Y, Zhang S, Dai N, et al. Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis. Gut 69: 224-230, 2020.","DOI":"10.1136\/gutjnl-2019-318365"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Okanobu H, Kohno T, Mouri R, et al. Efficacy of vonoprazan 10 mg compared with 20 mg for the initial treatment in patients with erosive esophagitis: a randomized pilot study. Esophagus 18: 669-675, 2021.","DOI":"10.1007\/s10388-020-00798-7"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Kusano M, Shimoyama Y, Sugimoto S, et al. Development and evaluation of FSSG: frequency scale for the symptoms of GERD. J Gastroenterol 39: 888-891, 2004.","DOI":"10.1007\/s00535-004-1417-7"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 45: 172-180, 1999.","DOI":"10.1136\/gut.45.2.172"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Miwa H, Yokoyama T, Hori K, et al. Interobserver agreement in endoscopic evaluation of reflux esophagitis using a modified Los Angeles classification incorporating grades N and M: a validation study in a cohort of Japanese endoscopists. Dis Esophagus 21: 355-363, 2008.","DOI":"10.1111\/j.1442-2050.2007.00788.x"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Nadaleto BF, Herbella FA, Patti MG. Gastroesophageal reflux disease in the obese: pathophysiology and treatment. Surgery 159: 475-486, 2016.","DOI":"10.1016\/j.surg.2015.04.034"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Braghetto I, Lanzarini E, Korn O, et al. Manometric changes of the lower esophageal sphincter after sleeve gastrectomy in obese patients. Obes Surg 20: 357-362, 2010.","DOI":"10.1007\/s11695-009-0040-3"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Thereaux J, Lesuffleur T, Czernichow S, et al. Do sleeve gastrectomy and gastric bypass influence treatment with proton pump inhibitors 4 years after surgery? A nationwide cohort. Surg Obes Relat Dis 13: 951-959, 2017.","DOI":"10.1016\/j.soard.2016.12.013"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. El Nakeeb A, Aldossary H, Zaid A, et al. Prevalence, predictors, and management of gastroesophageal reflux disease after laparoscopic sleeve gastrectomy: a multicenter cohort study. Obes Surg 32: 3541-3550, 2022.","DOI":"10.1007\/s11695-022-06264-w"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Gormsen J, Sanberg J, G\u00f6genur I, et al. Use of proton pump inhibitors after laparoscopic gastric bypass and sleeve gastrectomy: a nationwide register-based cohort study. Int J Obes 48: 1613-1619, 2024.","DOI":"10.1038\/s41366-024-01593-5"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Wu WY, Chang SC, Hsu JT, et al. Gastroesophageal reflux disease symptoms after laparoscopic sleeve gastrectomy: a retrospective study. J Pers Med 12: 1795, 2022.","DOI":"10.3390\/jpm12111795"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Sheppard CE, Sadowski DC, de Gara CJ, et al. Rates of reflux before and after laparoscopic sleeve gastrectomy for severe obesity. Obes Surg 25: 763-768, 2015.","DOI":"10.1007\/s11695-014-1480-y"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Sakurai Y, Mori Y, Okamoto H, et al. Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects - a randomised open-label cross-over study. Aliment Pharmacol Ther 42: 719-730, 2015.","DOI":"10.1111\/apt.13325"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Rapolti DI, Monrabal Lezama M, et al. Management of gastroesophageal reflux disease after sleeve gastrectomy: effectiveness of medical, endoscopic, and surgical therapies. J Laparoendosc Adv Surg Tech A 34: 581-602, 2024.","DOI":"10.1089\/lap.2024.0111"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Coleman HG, Xie SH, Lagergren J. The epidemiology of esophageal adenocarcinoma. Gastroenterology 154: 390-405, 2018.","DOI":"10.1053\/j.gastro.2017.07.046"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_8093-26\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:11:38Z","timestamp":1791605498000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_8093-26\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":28,"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.8093-26","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"8093-26"}}